Johnson & Johnson (JNJ)

JNJ on New York Consolidated

102.26USD
3 Mar 2015
Change (% chg)

$-0.96 (-0.93%)
Prev Close
$103.22
Open
$103.10
Day's High
$103.10
Day's Low
$101.81
Volume
4,517,280
Avg. Vol
9,291,070
52-wk High
$109.49
52-wk Low
$90.83

JNJ

Chart for JNJ

About

Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being.... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $281,413.31
Shares Outstanding(Mil.): 2,780.49
Dividend: 0.70
Yield (%): 2.77

Financials

  JNJ Industry Sector
P/E (TTM): 17.75 38.99 40.21
EPS (TTM): 5.70 -- --
ROI: 15.32 17.01 16.34
ROE: 22.70 17.53 17.27
Search Stocks

Deals of the day- Mergers and acquisitions

March 2 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:

02 Mar 2015

Cardinal to buy J&J vascular technology unit Cordis for $1.9 billion

NEW YORK - U.S. pharmaceutical and medical equipment maker Johnson & Johnson said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health for $1.9 billion, completing its exit from the cardiovascular stent business.

02 Mar 2015

UPDATE 3-Cardinal to buy J&J vascular technology unit Cordis for $1.9 bln

NEW YORK, March 2 - U.S. pharmaceutical and medical equipment maker Johnson & Johnson said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health for $1.9 billion, completing its exit from the cardiovascular stent business.

02 Mar 2015

Cardinal to buy J&J vascular technology unit Cordis for $1.9 bln

NEW YORK, March 2 - Cardinal Health said on Monday that it would buy Johnson & Johnson's Cordis vascular technology unit for $1.9 billion and that the acquisition would boost 2017 earnings by 20 cents per share.

02 Mar 2015

South Carolina court orders J&J to pay $136 mln in Risperdal case

- South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.

26 Feb 2015

South Carolina court orders Johnson & Johnson to pay $136 million in Risperdal case

- South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.

26 Feb 2015

South Carolina court orders J&J to pay $136 mln in Risperdal case

Feb 26 - South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.

26 Feb 2015

Pharmacyclics mulls sale; J&J, Novartis interested: Bloomberg

- Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson & Johnson and Novartis AG , Bloomberg reported.

25 Feb 2015

UPDATE 2-Pharmacyclics mulls sale; J&J, Novartis interested - Bloomberg

Feb 25 - Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson & Johnson and Novartis AG, Bloomberg reported.

25 Feb 2015

Pharmacyclics mulls selling itself; J&J, Novartis interested-Bloomberg

Feb 25 - Cancer drugmaker Pharmacyclics Inc is exploring a possible sale of the company and has attracted interest from Johnson & Johnson and Novartis AG, Bloomberg reported, citing people familiar the matter.

25 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks